Diabetes increases both N-ras and Ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential

In Vivo

Volumn 21, Issue 4, 2007, Pages 615-622

  Vairaktaris, Eleftherios ^a   Goutzanis, Lambros ^a   Kalokerinos, Giorgos ^a   Yannopoulos, Athanasios ^a   Yapijakis, Christos ^a   Vassiliou, Stavros ^a   Spyridonidou, Sofia ^a   Vylliotis, Antonis ^a   Nkenke, Emeka ^b   Lazaris, Andreas C ^a   Tesseromatis, Christina ^a   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Diabetes; ets 1; Histological grade; Immunohistochemistry; N ras; Oral squamous cell carcimoma

Indexed keywords

MONOCLONAL ANTIBODY; RAS PROTEIN; TRANSCRIPTION FACTOR ETS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; METASTASIS POTENTIAL; MOUTH CARCINOMA; MOUTH MUCOSA; NONHUMAN; PROTEIN EXPRESSION; RAT; SQUAMOUS CELL CARCINOMA;

EID: 34547731920     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med 328(3): 184-194, 1993.
2. Siavash H, Nikitakis NG and Sank JJ: Signal transducers and activators of transcription: insights into the molecular basis of oral cancer. Crit Rev Oral Biol Med 15(5): 298-307, 2004.
3. Williams HK: Molecular pathogenesis of oral carcinoma. J Clin Pathol 53: 165-172, 2000.
4. Rowinsky E, Windle JJ and Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999.
5. Adjei AA: Blocking Oneogenic Ras Signaling for Cancer Therapy. J Natl Cancer Inst 93(14): 1062-1074, 2001.
6. McKay IA, Paterson H, Brown R, Toksoz D, Marshall CJ and Hall A: N-ras and human cancer. Anticancer Res 6(3 Pt B): 483-490, 1986.
7. Paterson IC, Eveson JW and Prime SS: Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol 32B(3): 150-153, 1996.
8. Gutman A and Wasylyk B: The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 9: 2241-2246, 1990.
9. Wasylyk C, Gutman A, Nicholson R and Wasylyk B: c-ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 10: 1127-1134, 1991.
10. Stacey KJ, Fowles LF, Colman MS, Ostrowski MC and Hume DA: Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony stimulating factor. Mol Cell Biol 15: 3430-3441, 1995.
11. Wasylyk B, Hagman J and Gutierrez-Hartmann A: Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23(6): 213-216, 1998.
12. Kurpios NA, Sabolic NA, Shepherd TG, Fidalgo GM and Hassell JA: Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 8: 177-190, 1998.
13. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME and Gilmer TM: Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 104(11): 1337-1347, 1994.
14. McDonald JS, Wilson KM, Gartside P, Sonke RL, Pavelic L and Okum E: Immunohistochemical expression of N-ras oncogenes is a late event in head and neck carcinomas. Pathol Oncol Res 2(1-2): 30-33, 1996.
15. Wilson KM, Sonke RL, McDonald JS, Stambrook PJ, Pavelic LJ, Klusman P, Okum E, Neenan J, Gluckman JL and Pavelic ZP: Stage of disease confounds apparent relationship between levels, of N-ras and duration of survival in head and neck tumors. Eur J Cancer B Oral Onco1 32B(2): 73-75, 1996.
16. Suzui M, Yoshimi N, Tanaka T and Mori H: Infrequent Ha-ras mutations and absence of Ki-ras, N-ras, and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions. Mol Carcinog 14(4): 294-298, 1995.
17. Yeudall WA, Torrance LK, Elsegood KA, Speight P, Scully C and Prime SS: Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mueosal lesions. Eur J Cancer B Oral Oncol 29B(1): 63-67, 1993.
18. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, Kitahori Y, Yoshioka N, Kirita T and Sugimura M: Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 25(5): 232-238, 1996.
19. Pande P, Mathur M, Shukla NK and Ralhan R: Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J Pathol 189: 40-45, 1999.
20. Pande P, Soni S, Kaur J, Mathur M, Shukla NK and Ralhan R: Prognostic factors in betel and tobacco related oral cancer. Oral Oncol 38: 491-499, 2002.
21. Oikawa T and Yamada T: Molecular biology of the ETS family of transcription factors. Gene 303: 11-34, 2003.
22. Vairaktaris E, Papageorgiou G, Derka S, Moulavassili P, Nkenke E, Kessler P, Vassiliou S, Papakosta V, Spyridonidou S, Vylliotis A, Lazaris A, Anagnostopoulou S, Mourouzis C, Yapijakis C and Patsouris E: Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis. J Cancer Res Clin Oncol 133(4): 227-233, 2007.
23. Ponte E, Tabaj D, Manglione M and Melato M: Diabetes mellitus and oral disease. Acta Diabetol 38: 57-62, 2001.
24. Finney LS, Finney MO and Gonzales Campoy JM: What the mouth has to say about diabetes. Careful examinations can avert serious complications. Postgrad Med 102: 117-126, 1997.
25. Goutzanis L, Vairaktaris E, Yapijakis C, Kavantzas N, Nkenke E, Derka S, Vassiliou S, Acil Y, Kessler P, Stavrianeas N, Perrea D, Donta I, Scandalakis P and Patsouris E: Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Oral Oncol 43(2): 165-173, 2007.
26. Derka S, Vairaktaris E, Papakosta V, Vassiliou S, Acil Y, Vylliotis A, Spyridonidou S, Lazaris AC, Mourouzis C, Kokkori A, Moulavasili P, Perrea D, Donta I, Yapijakis C and Patsouris E: Cell proliferation and apoptosis culminate in early stages of oral oncogenesis. Oral Oncol 42(5): 540-550, 2006.
27. Fisher WE, Muscarella P, Boros LG and Schirmer WJ: Variable effect of streptozotocin-diabetes on the growth of hamster pancreatic cancer (H2T) in the Syrian hamster and nude mouse. Surgery 123: 315-320, 1998.
28. Dietrich T, Peter A, Reichart PA and Christian Scheifele C: Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncol 40: 158-163, 2004.
29. Ujpal M, Matos O, Bibok G and Szabo G: Incidence of diabetes mellitus in patients with malignant tumors of the oral cavity. Orv Hetil 143: 2731-2733, 2002.
30. Ujpal M, Matos O, Bibok G, Somogyi A, Szabo G and Suba Z: Diabetes and oral tumors in Hungary. Epidemiological correlations. Diabetes Care 27: 770-774, 2004.
31. White MF: IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 283: 413-422, 2002.
32. Zayzafoon, MVandenbunder B, Queva C, Desbiens X, Wernert N and Stehelin D: Expression of transcription factor c-ets-1 correlates with the occurrence of invasive processes during normal and pathological development. Invasion Metastasis 14: 198-209, 1995.